Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

INTRODUCTION: MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefit. Resistance mechanisms to dual EGFR-MET inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kaiwen, Du, Robyn, Roy-Chowdhuri, Sinchita, Li, Ziping T., Hong, Lingzhi, Vokes, Natalie, Elamin, Yasir Y., Hume, Celyne Bueno, Skoulidis, Ferdinandos, Gay, Carl M., Blumenschein, George, Fossella, Frank V., Tsao, Anne, Zhang, Jianjun, Karachaliou, Niki, O’Brate, Aurora, Gann, Claudia-Nanette, Lewis, Jeff, Rinsurongkawong, Waree, Lee, J. Jack, Gibbons, Don Lynn, Vaporciyan, Ara A., Heymach, John V., Altan, Mehmet, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462815/
https://www.ncbi.nlm.nih.gov/pubmed/37649681
http://dx.doi.org/10.1016/j.jtocrr.2023.100533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462815/
https://www.ncbi.nlm.nih.gov/pubmed/37649681
http://dx.doi.org/10.1016/j.jtocrr.2023.100533

Ejemplares similares